Antibodies Contract Manufacturing Market Size, Share & Trends Analysis Report, By Product (Monoclonal Antibodies, Polyclonal Antibodies, Others), By Source, By End-use, By Region, And Segment Forecasts, 2025 - 2030
Intraoperative Neuromonitoring Market Growth & Trends
The global intraoperative neuromonitoring market size is expected to reach USD 4.66 billion in 2030 and is anticipated to grow at a CAGR of 5.97% over the forecast period. This growth can be attributed to technological advancements, increasing awareness regarding the safety of the devices, and the growing geriatric population. The COVID-19 outbreak is expected to have a dual impact on the market. In March 2020, the American College of Surgeons (ACS) published a proposal to reduce, postpone, or cancel elective surgeries as COVID-19 cases grew quickly in the U.S., which is expected to hamper growth.
Moreover, according to a research study published in Elsevier journal (International Hemorrhagic Stroke Association; Jan 2021), up to 36% of hospitalized COVID-19 patients might exhibit neurological symptoms, and there were several cases related to ischemic & hemorrhagic infarction. In addition, another recent research study published in Neurology Online Journal in June 2021 proposed that the COVID-19 virus might be responsible for patients acquiring novel neurological diseases. Owing to the growth of new diseases, there is a higher risk of in-hospital mortality and a low discharge rate. These characteristics are expected to result in lucrative growth over the forecast period.
Furthermore, the market is expected to witness growth due to the increasing number & affordability of neurosurgeries and the growing emphasis on patient safety in surgeries. Hospitals are adopting Intraoperative Neuromonitoring (IONM) in a wide spectrum of surgeries, as it reduces the number of revision surgeries and results in fewer postoperative complications & cases of permanent impairment.
Intraoperative Neuromonitoring Market Report Highlights
- By type, the insourced segment accounted for the largest share of 52.72% in 2024. This can be attributed to growing awareness among physicians as well as patients about the benefits of IONM, which results in the hospitals utilizing IONM during complex procedures. This is a key reason for the dominance of insourced IONM in the market
- By region, North America accounted for the largest share of 49.35% in 2024. Favorable reimbursement scenarios along with technological advancements can be attributed to this dominance
- The intraoperative neuromonitoring market in Europe is anticipated to grow fastest with a CAGR of 6.38% during the forecast period
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.1.1. Approach 1: Commodity flow approach
- 1.7.2. Volume price analysis (Model 2)
- 1.7.2.1. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Antibody Contract Manufacturing Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Drivers Analysis
- 3.2.2. Market Restraints Analysis
- 3.2.3. Industry Challenges
- 3.3. Market Analysis Tools
- 3.3.1. Porter’s Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Analysis
- Chapter 4. Antibody Contract Manufacturing Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Product Movement Analysis
- 4.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by Product, 2018 - 2030 (USD Million)
- 4.4. Monoclonal Antibodies
- 4.4.1. Monoclonal Antibodies Market Estimates & Forecasts, by Source, 2018 - 2030 (USD Million)
- 4.5. Polyclonal Antibodies
- 4.5.1. Polyclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Others
- 4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- Chapter 5. Source Business Analysis
- 5.1. Segment Dashboard
- 5.2. Source Movement Analysis
- 5.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by Source, 2018 - 2030 (USD Million)
- 5.4. Mammalian Source
- 5.4.1. Mammalian Source Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Microbial
- 5.5.1. Microbial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- Chapter 6. End Use Business Analysis
- 6.1. Segment Dashboard
- 6.2. End Use Movement Analysis
- 6.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by End Use, 2018 - 2030 (USD Million)
- 6.4. Biopharmaceutical Companies
- 6.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Research Laboratories
- 6.5.1. Research Laboratories Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- Chapter 7. Antibody Contract Manufacturing Market: Regional Estimates & Trend Analysis
- 7.1. Regional market share analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. North America
- 7.3.1. U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Competitive Scenario
- 7.3.2.3. Regulatory Landscape
- 7.3.2.4. U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Canada
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Competitive Scenario
- 7.3.3.3. Regulatory Landscape
- 7.3.3.4. Canada Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. Mexico
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Competitive Scenario
- 7.3.4.3. Regulatory Landscape
- 7.3.4.4. Mexico Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Europe
- 7.4.1. Europe Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. UK
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Landscape
- 7.4.2.4. UK Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Germany
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Landscape
- 7.4.3.4. Germany Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. France
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Landscape
- 7.4.4.4. France Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. Italy
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Competitive Scenario
- 7.4.5.3. Regulatory Landscape
- 7.4.5.4. Italy Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Spain
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Competitive Scenario
- 7.4.6.3. Regulatory Landscape
- 7.4.6.4. Spain Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Denmark
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Competitive Scenario
- 7.4.7.3. Regulatory Landscape
- 7.4.7.4. Denmark Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.8. Sweden
- 7.4.8.1. Key Country Dynamics
- 7.4.8.2. Competitive Scenario
- 7.4.8.3. Regulatory Landscape
- 7.4.8.4. Sweden Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.9. Norway
- 7.4.9.1. Key Country Dynamics
- 7.4.9.2. Competitive Scenario
- 7.4.9.3. Regulatory Landscape
- 7.4.9.4. Norway Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Asia Pacific Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. China
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Landscape
- 7.5.2.4. China Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Japan
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Landscape
- 7.5.3.4. Japan Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. India
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Landscape
- 7.5.4.4. India Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. South Korea
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Landscape
- 7.5.5.4. South Korea Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Australia
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Landscape
- 7.5.6.4. Australia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Thailand
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Landscape
- 7.5.7.4. Thailand Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Latin America
- 7.6.1. Latin America Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Brazil
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Landscape
- 7.6.2.4. Brazil Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Landscape
- 7.6.3.4. Argentina Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Middle East and Africa
- 7.7.1. Middle East and Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Landscape
- 7.7.2.4. Saudi Arabia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. UAE
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Landscape
- 7.7.3.4. UAE Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.4. South Africa
- 7.7.4.1. Key Country Dynamics
- 7.7.4.2. Competitive Scenario
- 7.7.4.3. Regulatory Landscape
- 7.7.4.4. South Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.5. Kuwait
- 7.7.5.1. Key Country Dynamics
- 7.7.5.2. Competitive Scenario
- 7.7.5.3. Regulatory Landscape
- 7.7.5.4. Kuwait Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Participant Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
- 8.4. Company Profiles
- 8.4.1. Lonza
- 8.4.1.1. Participant’s Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Service Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Samsung Biologics
- 8.4.2.1. Participant’s Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Service Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. WuXi Biologics
- 8.4.3.1. Participant’s Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Service Benchmarking
- 8.4.4. Charles River Laboratories
- 8.4.4.1. Participant’s Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Service Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. FUJIFILM Holdings Corporation
- 8.4.5.1. Participant’s Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Service Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. Boehringer Ingelheim GmbH
- 8.4.6.1. Participant’s Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Service Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. AGC Biologics
- 8.4.7.1. Participant’s Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Service Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Cytovance Biologics, Inc.
- 8.4.8.1. Participant’s Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Service Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. EMERGENT
- 8.4.9.1. Participant’s Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Service Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. Thermo Fisher Scientific, Inc.
- 8.4.10.1. Participant’s Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Service Benchmarking
- 8.4.10.4. Strategic Initiatives
- 8.4.10.5. Strategic Initiatives
- 8.4.11. Catalent, Inc
- 8.4.11.1. Participant’s Overview
- 8.4.11.2. Financial Performance
- 8.4.11.3. Service Benchmarking
- 8.4.11.4. Strategic Initiatives
- 8.4.12. Laboratory Corporation of America Holdings
- 8.4.12.1. Participant’s Overview
- 8.4.12.2. Financial Performance
- 8.4.12.3. Service Benchmarking
- 8.4.12.4. Strategic Initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook